Supplementary material

Supplementary material 1. Table S1. Clinicodemographic characteristics of healthy individuals (control group) (n=11). Table S2. N-glycan number, structure, accurate mass, mass used for quantification, corresponding adduct and the heavy reference number used for LC-MS and MALDI MS quantification methods Supplementary material 2. MS/MS of permethylated and deuterated N-glycans found in serum. PDF files Supplementary material 3. Raw data of all compositions found in serum and tissues samples by MALDI-TOF/MS and LC/MS/MS analysis. Excel file. Sheet 1. List of -CH3/-CD3 ratios from all 33 ion signals detected in serum of cancer patients (n=13) and controls (n=11), by MALDI/MS Sheet 2. List of -CH3/-CD3 ratios from all 90 ion signals identified in serum of cancer patients (n=13) and controls (n=11), by LC-MS/MS Sheet 3. List of -CH3/-CD3 ratios from all 13 ion signals (>5% intensity) detected in cancer and normal tissue of cancer patients (n=13) by MALDI/MS Sheet 4. List of -CH3/-CD3 ratios from all 35 ion signals ( signal/noise > 1000) identified in cancer and normal tissue of cancer patients (n=13) by LC-MS/MS Supplementary material 4. Figures S1 and S2 box-plots distribution of all N-glycans identified in serum, by MALDI-TOF/MS and LC/MS/MS analysis Figures S3 to S15 spectra of all MALDI-TOF/MS acquisitions of tumour tissues from colon cancer patients (n=13). Figures S16 and S17 box-plots distribution of all N-glycans identified in tissues by MALDI-TOF/MS and LC/MS/MS analysi